Global X Genomics & Biotechnology ETF
GNOM
9 hedge funds and large institutions have $28.3M invested in Global X Genomics & Biotechnology ETF in 2020 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 1 closing their positions.
170% more capital invested
Capital invested by funds: $10.5M → $28.3M (+$17.8M)
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
13% more funds holding
Funds holding: 8 → 9 (+1)
1.82% more ownership
Funds ownership: 15.31% → 17.13% (+1.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
+$8.37M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$3.36M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$496K |
| 4 |
BFEC
Benjamin F. Edwards & Company
St. Louis,
Missouri
|
+$2.37K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AA
Advisory Alpha
Holland,
Michigan
|
-$14K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$13.8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Citigroup
New York
| $13.2M | – | – | – |
|
|
2
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| $9.44M | +$8.37M | +134,336 | New |
|
|
3
UBS Group
Zurich,
Switzerland
| $4.85M | +$3.36M | +54,029 | +359% |
|
|
4
Citadel Advisors
Miami,
Florida
| $559K | +$496K | +7,957 | New |
|
|
5
Royal Bank of Canada
Toronto,
Ontario, Canada
| $148K | -$13.8K | -222 | -10% |
|
6
Osaic Holdings
Scottsdale,
Arizona
| $72K | – | – | – |
|
7
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| $24K | – | – | – |
|
|
BFEC
8
Benjamin F. Edwards & Company
St. Louis,
Missouri
| $16K | +$2.37K | +38 | +20% |
|
|
APA
9
American Portfolios Advisors
Holbrook,
New York
| $11K | – | – | – |
|
|
AA
10
Advisory Alpha
Holland,
Michigan
| – | -$14K | -238 | Closed |
|
GNOM Hedge Fund Activity: Q2 2020 in Review
9 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Global X Genomics & Biotechnology ETF (GNOM) for Q2 2020, worth a combined $28.3M — up 170% from $10.5M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new GNOM positions and 1 closed out — a net gain of 1 holder — while 2 added to existing stakes and 1 trimmed.
The largest buyer was PNC Financial Services Group, opening a new position worth an estimated $8.37M. The largest seller was Advisory Alpha, exiting entirely with an estimated $14K sold.
- 9 institutional investors held Global X Genomics & Biotechnology ETF (GNOM) as of Q2 2020, up from 8 in Q1 2020.
- Funds reported $28.3M of Global X Genomics & Biotechnology ETF stock for Q2 2020, up 170% quarter-over-quarter.
- 2 funds opened new Global X Genomics & Biotechnology ETF positions in Q2 2020 and 1 closed out, a net change of +1 holder.
- The largest Global X Genomics & Biotechnology ETF buyer in Q2 2020 was PNC Financial Services Group, an estimated $8.37M added.
- The largest Global X Genomics & Biotechnology ETF seller in Q2 2020 was Advisory Alpha, an estimated $14K sold.
Based on aggregated 13F filings for Q2 2020.